A Phase II Open Label Study of RA-18C3 in Subjects With Pyoderma Gangrenosum
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs MABp1 (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- Sponsors XBiotech
- 23 Jan 2017 Status changed from recruiting to completed.
- 22 Dec 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
- 22 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.